Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01857934Phase 2Completed

Therapy for Children With Advanced Stage Neuroblastoma

Role: collaborator

NCT02425904Phase 2Active Not Recruiting

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Role: collaborator

NCT02932956Phase 1Active Not Recruiting

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Role: collaborator

NCT03107988Phase 1Completed

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Role: collaborator

NCT03654716Phase 1Completed

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Role: collaborator

NCT01700946Phase 2Completed

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Role: collaborator

NCT02433483Phase 2Terminated

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

Role: collaborator

All 7 trials loaded